相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Early post-transplant recurrence of oxalate nephropathy in a patient with primary hyperoxaluria type 1, despite pretransplant lumasiran therapy
Nizar Joher et al.
KIDNEY INTERNATIONAL (2022)
Perspectives in primary hyperoxaluria - historical, current and future clinical interventions
Kevin Shee et al.
NATURE REVIEWS UROLOGY (2022)
The effect of lumasiran therapy for primary hyperoxaluria type 1 in small infants
Marie-Noelle Meaux et al.
PEDIATRIC NEPHROLOGY (2022)
Clinical characterization of primary hyperoxaluria type 3 in comparison with types 1 and 2
Prince Singh et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2022)
Case Report: Sustained Efficacy of Lumasiran at 18 Months in Primary Hyperoxaluria Type 1
Benedetta Chiodini et al.
FRONTIERS IN PEDIATRICS (2022)
Primary Hyperoxaluria Type 3 Can Also Result in Kidney Failure: A Case Report
Prince Singh et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2022)
New therapeutics for primary hyperoxaluria type 1
Pegah Dejban et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2022)
Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria
Bernd Hoppe et al.
KIDNEY INTERNATIONAL (2022)
In vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria
Rebeca Martinez-Turrillas et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2022)
New salicylic acid derivatives, double inhibitors of glycolate oxidase and lactate dehydrogenase, as effective agents decreasing oxalate production
Maria Dolores Moya-Garzon et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
Is stiripentol truly effective for treating primary hyperoxaluria?
Cristina Martin-Higueras et al.
CLINICAL KIDNEY JOURNAL (2021)
Effects of Oxalobacter formigenes in subjects with primary hyperoxaluria Type 1 and end-stage renal disease: a Phase II study
Bernd Hoppe et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)
Lumasiran: First Approval
Lesley J. Scott et al.
DRUGS (2021)
Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria
Gema Ariceta et al.
KIDNEY INTERNATIONAL REPORTS (2021)
Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1 A Placebo-Controlled Randomized Clinical Trial
Yaacov Frishberg et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)
A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3
Cristina Martin-Higueras et al.
KIDNEY INTERNATIONAL (2021)
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
Sander F. Garrelfs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Transplantation outcomes in patients with primary hyperoxaluria: a systematic review
Elisabeth L. Metry et al.
PEDIATRIC NEPHROLOGY (2021)
Nedosiran Dramatically Reduces Serum Oxalate in Dialysis-Dependent Primary Hyperoxaluria 1: A Compassionate Use Case Report
Kevin Shee et al.
UROLOGY (2021)
Primary hyperoxaluria diagnosed after kidney transplant: A review of the literature and case report of aggressive renal replacement therapy and lumasiran to prevent allograft loss
Hillarey K. Stone et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2021)
Oxalic Cardiomyopathy Could it Influence Treatment Plans in Patients With Primary Hyperoxaluria Type 1?
Alessandro Di Toro et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Dual Glycolate Oxidase/Lactate Dehydrogenase A Inhibitors for Primary Hyperoxaluria
Jinyue Ding et al.
ACS MEDICINAL CHEMISTRY LETTERS (2021)
Primary Hyperoxaluria Type 1 (PH1) Presenting With End-Stage Kidney Disease and Cutaneous Manifestations in Adulthood: A Case Report
Penelope Poyah et al.
CANADIAN JOURNAL OF KIDNEY HEALTH AND DISEASE (2021)
Primary hyperoxaluria type 2 successfully treated with combined liver-kidney transplantation after failure of isolated kidney transplantation
Arnaud Del Bello et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2020)
Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria
Tracy L. McGregor et al.
ELIFE (2020)
Stiripentol fails to lower plasma oxalate in a dialysis-dependent PH1 patient
Caroline Kempf et al.
PEDIATRIC NEPHROLOGY (2020)
Stiripentol identifies a therapeutic target to reduce oxaluria
Emmanuel Letavernier et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2020)
The Ocular Phenotype in Primary Hyperoxaluria Type 1
Johannes Birtel et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2019)
Stiripentol protects against calcium oxalate nephrolithiasis and ethylene glycol poisoning
Marine Le Dudal et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Generation of induced pluripotent stem cells-derived hepatocyte-like cells for ex vivo gene therapy of primary hyperoxaluria type 1
Julie Esteve et al.
STEM CELL RESEARCH (2019)
Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up
Sander F. Garrelfs et al.
KIDNEY INTERNATIONAL (2019)
Generation of an induced pluripotent stem cell line (CIMAi001-A) from a compound heterozygous Primary Hyperoxaluria Type I (PH1) patient carrying p.G170R and p.R122*mutations in the AGXT gene
Rebeca Martinez-Turrillas et al.
STEM CELL RESEARCH (2019)
Salicylic Acid Derivatives Inhibit Oxalate Production in Mouse Hepatocytes with Primary Hyperoxaluria Type 1
Maria Dolores Moya-Garzon et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Translation inhibition corrects aberrant localization of mutant alanine-glyoxylate aminotransferase: possible therapeutic approach for hyperoxaluria
Ruth Belostotsky et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2018)
Metabolite diagnosis of primary hyperoxaluria type 3
Lawrence Greed et al.
PEDIATRIC NEPHROLOGY (2018)
How Simian Virus 40 Hijacks the Intracellular Protein Trafficking Pathway to Its Own Benefit ... and Ours
Miguel G. Toscano et al.
FRONTIERS IN IMMUNOLOGY (2018)
Nephrolithiasis and Nephrocalcinosis in Childhood-Risk Factor-Related Current and Future Treatment Options
Alexander Weigert et al.
FRONTIERS IN PEDIATRICS (2018)
Metabolic profile and impact of diet in patients with primary hyperoxaluria
Roswitha Siener et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2018)
Novel therapeutic approaches in primary hyperoxaluria
Alexander Weigert et al.
EXPERT OPINION ON EMERGING DRUGS (2018)
Combined Liver-Kidney Transplantation for Primary Hyperoxaluria Type 2: A Case Report
T. Dhondup et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2018)
A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria
Bernd Hoppe et al.
PEDIATRIC NEPHROLOGY (2017)
Molecular therapy of primary hyperoxaluria
Cristina Martin-Higueras et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2017)
Systematic assessment of urinary hydroxy-oxo-glutarate for diagnosis and follow-up of primary hyperoxaluria type III
Ada Ventzke et al.
PEDIATRIC NEPHROLOGY (2017)
Generation of a Vero-Based Packaging Cell Line to Produce SV40 Gene Delivery Vectors for Use in Clinical Gene Therapy Studies
Miguel G. Toscano et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2017)
Assessment of the low inhibitory specificity of oxamate, aminooxyacetate and dichloroacetate on cancer energy metabolism
Rafael Moreno-Sanchez et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2017)
Predictors of Incident ESRD among Patients with Primary Hyperoxaluria Presenting Prior to Kidney Failure
Fang Zhao et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1
Chaitali Dutta et al.
MOLECULAR THERAPY (2016)
Glycolate Oxidase Is a Safe and Efficient Target for Substrate Reduction Therapy in a Mouse Model of Primary Hyperoxaluria Type I
Cristina Martin-Higueras et al.
MOLECULAR THERAPY (2016)
Generation and characterization of human iPSC lines derived from a Primary Hyperoxaluria Type I patient with p.I244T mutation
Natalia Zapata-Linares et al.
STEM CELL RESEARCH (2016)
The primary hyperoxalurias: A practical approach to diagnosis and treatment
Sally-Anne Hulton
INTERNATIONAL JOURNAL OF SURGERY (2016)
High throughput cell-based assay for identification of glycolate oxidase inhibitors as a potential treatment for Primary Hyperoxaluria Type 1
Mengqiao Wang et al.
SCIENTIFIC REPORTS (2016)
Pyridoxamine and pyridoxal are more effective than pyridoxine in rescuing folding-defective variants of human alanine: glyoxylate aminotransferase causing primary hyperoxaluria type I
Elisa Oppici et al.
HUMAN MOLECULAR GENETICS (2015)
Pyridoxamine Dihydrochloride in Diabetic Nephropathy (PIONEER-CSG-17): Lessons Learned from a Pilot Study
Jamie P. Dwyer et al.
NEPHRON (2015)
Vitamin B6 in Primary Hyperoxaluria I: First Prospective Trial after 40 Years of Practice
Heike Hoyer-Kuhn et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type
Giorgia Mandrile et al.
KIDNEY INTERNATIONAL (2014)
Pharmacologic rescue of an enzyme-trafficking defect in primary hyperoxaluria 1
Non Miyata et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Four of the Most Common Mutations in Primary Hyperoxaluria Type 1 Unmask the Cryptic Mitochondrial Targeting Sequence of Alanine:glyoxylate Aminotransferase Encoded by the Polymorphic Minor Allele
Sonia Fargue et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1 beta secretion
Shrikant R. Mulay et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy
Felix Knauf et al.
KIDNEY INTERNATIONAL (2013)
Primary Hyperoxaluria
Pierre Cochat et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Primary hyperoxalurias: Disorders of glyoxylate detoxification
Eduardo Salido et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2012)
Biochemical analyses are instrumental in identifying the impact of mutations on holo and/or apo-forms and on the region(s) of alanine:glyoxylate aminotransferase variants associated with Primary Hyperoxaluria Type I
Elisa Oppici et al.
MOLECULAR GENETICS AND METABOLISM (2012)
An update on primary hyperoxaluria
Bernd Hoppe
NATURE REVIEWS NEPHROLOGY (2012)
Liver cell transplantation in severe infantile oxalosis-a potential bridging procedure to orthotopic liver transplantation?
Bodo B. Beck et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2012)
Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment
Pierre Cochat et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2012)
Molecular Requirements for Peroxisomal Targeting of Alanine-Glyoxylate Aminotransferase as an Essential Determinant in Primary Hyperoxaluria Type 1
Krisztian Fodor et al.
PLOS BIOLOGY (2012)
Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter
Marguerite Hatch et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2011)
Primary Hyperoxaluria Type III Gene HOGA1 (Formerly DHDPSL) as a Possible Risk Factor for Idiopathic Calcium Oxalate Urolithiasis
Carla G. Monico et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Phenotypic Correction of a Mouse Model for Primary Hyperoxaluria With Adeno-associated Virus Gene Transfer
Eduardo Salido et al.
MOLECULAR THERAPY (2011)
Mutations in DHDPSL Are Responsible For Primary Hyperoxaluria Type III
Ruth Belostotsky et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2010)
Transplantation Outcomes in Primary Hyperoxaluria
E. J. Bergstralh et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2010)
Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells
S. Tamir Rashid et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome
Jerome Harambat et al.
KIDNEY INTERNATIONAL (2010)
The tubular epithelium in the initiation and course of intratubular nephrocalcinosis
Benjamin A. Vervaet et al.
UROLOGICAL RESEARCH (2010)
Hyperoxaluria Is Reduced and Nephrocalcinosis Prevented with an Oxalate-Degrading Enzyme in Mice with Hyperoxaluria
Danica Grujic et al.
AMERICAN JOURNAL OF NEPHROLOGY (2009)
Molecular Basis of Reduced Pyridoxine 5′-Phosphate Oxidase Catalytic Activity in Neonatal Epileptic Encephalopathy Disorder
Faik N. Musayev et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Transplantation Procedures in Children With Primary Hyperoxaluria Type 1: Outcome and Longitudinal Growth
Florian Brinkert et al.
TRANSPLANTATION (2009)
In Vivo and in Vitro Examination of Stability of Primary Hyperoxaluria-associated Human Alanine: Glyoxylate Aminotransferase
Erin D. Hopper et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Correction of hyperoxaluria by liver repopulation with hepatocytes in a mouse model of primary hyperoxaluria type-1
Jinlan Jiang et al.
TRANSPLANTATION (2008)
Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy
Mark E. Williams et al.
AMERICAN JOURNAL OF NEPHROLOGY (2007)
Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1
F. Illies et al.
KIDNEY INTERNATIONAL (2006)
Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1
B. Hoppe et al.
KIDNEY INTERNATIONAL (2006)
Oxalobacter sp reduces urinary oxalate excretion by promoting enteric oxalate secretion
M Hatch et al.
KIDNEY INTERNATIONAL (2006)
Pyridoxamine lowers oxalate excretion and kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria
JI Scheinman et al.
UROLOGICAL RESEARCH (2005)
Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele
CG Monico et al.
KIDNEY INTERNATIONAL (2005)
Intestinal transport of an obdurate anion: oxalate
M Hatch et al.
UROLOGICAL RESEARCH (2005)
The primary hyperoxalurias: An algorithm for diagnosis
DS Milliner
AMERICAN JOURNAL OF NEPHROLOGY (2005)
Implications of genotype and enzyme phenotype in pyridoxine response of patients with type I primary hyperoxaluria
CG Monico et al.
AMERICAN JOURNAL OF NEPHROLOGY (2005)
A 20-year experience of combined liver/kidney transplantation for primary hyperoxaluria (PH1): The European PH1 Transplant Registry experience 1984-2004
NV Jamieson
AMERICAN JOURNAL OF NEPHROLOGY (2005)
Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: A potential therapy for primary hyperoxaluria
SV Chetyrkin et al.
KIDNEY INTERNATIONAL (2005)
A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria
B Hoppe et al.
PEDIATRIC NEPHROLOGY (2003)
Primary hyperoxaluria type 1 in The Netherlands: prevalence and outcome
CS van Woerden et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2003)
Combined liver-kidney and kidney-alone transplantation in primary hyperoxaluria
CG Monico et al.
LIVER TRANSPLANTATION (2001)
分享论文
